Suggested remit: To appraise the clinical and cost effectiveness of lorlatinib within its marketing authorisation for untreated ALK-positive advanced non-small cell lung cancer.
Status Proposed
Process STA 2018
ID number 3896

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
11 March 2021 - 12 April 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance